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Fluid phase generation of terminal complement complex as a novel
index of bioincompatibility. Blood membrane interactions in hemodial-
ysis have been shown to trigger complement (C) activation, As indica-
tors of C-activation the anaphylatoxins (C3a and C5a) are problematical
because of methodological difficulties and their kinetic properties. We
developed a sensitive and specific micro-ELISA using a monoclonal
antibody against neoantigens on the terminal complement complex
(TCC); highly purified human TCC served as standard. Concentrations
of ICC were measured in single-path perfusion systems (in vitro) and in
the blood lines (arterial inlet; venous outlet) of patients on hemodialysis
using steam-sterilized or ETO-sterilized dialyzers with the following
membranes: cuprophan (CU), hemophan (HE) and polysulfone F6 (PS),
respectively. All dialyzers with identical geometry were run under
identical conditions. All membranes tested caused continuously ongo-
ing net generation of TCC. In vitro, contact of serum with CU
minidialyzers resulted in fivefold higher net release of TCC compared
with HE and PS. In vivo TCC concentration-time profiles differed
significantly between membranes in the rank order CU >>> HE > PS
(mean basal concentration 58 x 10 M; peak increase over baseline
with CU 40-fold, HE fourfold, PS threefold). In addition, more TCC
was generated from the same dialyzers with ETO than steam steriliza-
tion. TCC differed from C3a and C5a in the following respects: (i) lower
detection limit (4 x l0 vs. <5 X i0 M for both C-anaphylatoxins);
(ii) higher relative increment (inlet) during CU dialysis (25-fold vs.
eightfold and twofold, respectively); (iii) C-anaphylatoxins yielded the
same ranking (CU >> HE > PS), but TCC concentrations were not a
linear function of C3a or C5a concentrations, respectively. Kinetic
analysis (Bateman function) showed significant differences of invasion
constants between membranes, that is, CU 0.088 min, HE 0.09, PS
0.168. The net amount of TCC released from the dialyzer was calculated
under certain assumptions. It was 75.5 mg/4 hr for CU, 7.3 for HE and
5.0 for PS. The elimination constant was also dependent on the type of
membrane. Using flow cytofluorometry and immunohistochemical
methods (APAAP), TCC was demonstrated on membranes of granulo-
cytes obtained during dialysis; this is compatible with potential in vivo
cell activation. Generation of PGE2 and TNF,, by adherent monocytes
induced by cuprophan was C8 dependent: levels were significantly
increased by addition of CS to C8 deficient human serum concomitantly
with generation of TCC. We conclude that TCC: (i) is a sensitive index
of biocompatibility; (ii) provides information that is complementary to
that obtained using C3a and C5a; (iii) may be involved in the genesis of
some bioincompatibility phenomena.
Following the breakthrough observation of Craddock et al [1,
2] that cleavage of C3 occurs upon contact of blood with
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cuprophan (cuprammonium) in vitro or in vivo, activation of the
complement by the alternative pathway has been recognized as
a major element in bioincompatibility reactions of patients
dialyzed with cuprophan membranes. In subsequent studies,
Chenoweth, Cheung and Henderson [3] and others [4, 5]
reported that C5a was consistently generated upon blood!
membrane contact. After interactions with their specific recep-
tors, the anaphylatoxins C3a and C5a provide potent activation
signals to PMN and mononuclear cells [6, 7]. Consequently,
bioincompatibility reactions were thought to be mediated to a
major extent via cleavage of C3 and C5, respectively. Measure-
ments of other components of the complement system were
limited because adequate methods to monitor steps subsequent
to CS were not available for studies in vivo.
The terminal complement complex (TCC) is generated by
sequential assembly on target membranes of five precursor
proteins (C5b, C6, C7, C8, C9) to form a multimolecular
membrane attack complex. Its assembling precursor molecules
undergo a hydrophylic-amphiphilic transition. This involves
conformational reorganization by protein-protein interactions
which expose epitopes (neoantigens) that can be recognized by
specific antibodies [8, 9]. The complex inserts into membranes
and exerts membranolytic effects. As an alternative, the C5b-9
complex can react with plasmatic S-protein [101, a scavenger
which keeps the complex inactive in the fluid phase. Active
membrane-bound TCC complexes interfere not only with the
function of the membrane as a permeability bamer, but, in
addition, constitute a potent signal for activation of nucleated
cells.
We reasoned that TCC may provide a novel index of biocom-
patibility, yielding information complementary to and indepen-
dent of the C-anaphylatoxins. Using a monoclonal antibody
[11], a specific micro-ELISA was developed to assess TCC in
the fluid phase.
Methods
Analytical procedures
ELISA for the terminal complement complex (TCC). Detec-
tion of TCC was based on a double-sandwich ELISA system
using a recently described monoclonal antibody (Mab) against
TCC neoantigen [11]. Its specificity was verified using dot-blot
analysis with highly purified monomeric or polymenzed C9 [12,
13]. Microtiter plates (Greiner Co., NUrtingen, FRG) were
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coated with anti-TCC at a final concentration of 0.15 xg/we1l
diluted in a 0.1 M sodium carbonate buffer, pH 9.8 for 16 hours
at 4°C. After blocking the remaining binding sites using 2%
casein in 0.1 M PBS, pH 7.2 for 30 minutes, plates were washed
with 0.01 M PBS/0.1% Tween 20 and immediately used for the
assay. EDTA plasma samples were diluted 1:3 to 1:50 in
PBS/Tween containing 10 mM EDTA, pH 7.2. Specimens of 100
.d each were incubated in duplicates for 90 minutes at room
temperature. After washing, bound TCC was detected by rabbit
anti-C5 (Dakopatts Co., Hamburg, FRG) followed by mouse
anti-rabbit IgG (H&L), conjugated with alkaline phosphatase
(Dianova Co., Hamburg, FRG).
The enzymatic activity was assessed using para-nitrophe-
nylphosphate (p-NPP, I mg/mi) in I M diethanolamine buffer,
pH 9.8 and measured by a software supported microplate
reader (Vmax, Molecular Devices Co., Palo Alto, California,
USA) at 405 nm against a reference wavelength of 650 nm.
Concentrations were calculated using a four parameter fit in an
ELISA software program. The assay was calibrated using
dilutions from yeast activated serum (100 mg freeze-dried
baker's yeast per ml pooled human serum, incubated for 2 hr at
37°C and centrifuged with 6000 g for 30 mm). Absolute concen-
trations and molar concentrations were calculated by compar-
ing with a purified human TCC (SC5b-9) standard, assuming a
molecular weight of approximately 1.000 kD for TCC [14].
Isolation of the terminal complement complex (SC5b-9).
SC5b-9 was purified from 20 ml yeast activated serum. After
precipitation by ammonium sulfate (40% saturation) and subse-
quently by PEG 4000 (10%), the pellet was reconstituted in 0.05
M TBS, pH 7.4 (10 mrvi EDTA, 0.02% NaN3) and applied on a
sucrose layer to a gel filtration column (sephacryl S 400 HR, 100
x 3.8 cm; Pharmacia Co., Freiburg, FRG). The resulting
homogenous peak of high molecular weight material was reac-
tive with anti-TCC (ELISA). The fraction was passed over a
G-25 column (Pharmacia Co., Freiburg, FRG) equilibrated with
20 mrvi Tris-HC1, pH 8.0. The fraction in the void volume was
subjected to ion exchange chromatography (Pharmacia Co.,
FPLC, MONO Q) and eluted with a linear gradient from 0 to
1000 mM NaCl. TCC, as detected by ELISA, peaked at a
concentration of 400 msr NaCl. Protein concentrations were
determined by protein microassay (BIORAD Co., MUnchen,
FRG) calibrated with human serum albumin. Purity of the final
product was checked by SDS-PAGE and silver staining or
immunoblotting.
Gel electrophoresis and immunoblotting. TCC-positive frac-
tions were analyzed on polyacrylamide gradient gels (T =2 to
10%, C = 5%) in SDS containing sample buffer according to the
method of Laemmli [15] under non-reducing conditions. Protein
pattern was visualized by silver staining according to Morrissey
[161. To examine the specificity of the calibration the same
fractions were electrophoretically transferred to cellulose ni-
trate membranes (BA-85; Schleicher & SchUll Co., Dassel,
FRG). After blocking residual binding sites using 0.01 M PBS
containing 0.3% Tween 20, separate strips were incubated with
polyclonal antibodies against CS (Dakopatts Co., Hamburg,
FRG), C6 (ICN-Miles Co., Naperville, Illinois, USA), C7, C8
(Genzyme Co., IC-Chemicals, MUnchen, FRG), C9 and S-
protein (Behring Co., Marburg, FRG). In separate runs we used
monoclonal antibodies against the respective antigens (Gen-
zyme Co. and Bioclin Co., Cardiff, U.K., respectively). The
protein bands were detected with the corresponding peroxidase
labelled antibodies and visualized using diaminobenzidine in
PBS.
Measurements of C3a and C5a. The concentrations of the
anaphylatoxins C3a and C5a were analyzed in commercially
available radioimmunoassays (Amersham Buchler Co., Braun-
schweig, FRG) according to the instructions of the manufac-
turer. In a first step, plasma samples were treated with the
commercial precipitant. For CSa measurements supernatant
aliquots were used undiluted; for C3a they were diluted three-
to 30-fold with isotonic saline containing 10 mM EDTA at pH
7.2. Higher speed of centrifugation was chosen for all centrifu-
gation steps to achieve higher reproducibility.
Immunocytochemical detection of TCC on cell membranes.
To detect TCC deposited on cell membranes (membrane attack
phase) we performed either flow cytofluorometry or immuno-
cytochemical staining (APAAP or immunofluorescence) on
cytocentrifuge (Shandon Co., Frankfurt, FRG) slide prepara-
tions of peripheral blood cells. Whole blood samples were
drawn during dialysis from the extracorporeal circuit before and
after contact of blood with cuprophan membranes within the
first 45 minutes of dialysis. EDTA (10 mM) and NaN3 (0.1%)
were immediately added to blood samples, which were cooled
to 4°C in order to avoid further complement activation and to
reduce internalization or shedding of cell bound TCC. Polymor-
phonuclear cells were harvested from the buffy coat after low
speed centrifugation (200 g, 20 mm, 4°C) and washed with PBS,
pH 7.4 containing 10 mrvt EDTA and 0.1% NaN3.
Preparation for flow cytofluorometry. White cells from 0.1 ml
whole blood were incubated with the monoclonal antibody
against TCC neoantigens [11] or mouse control ascites (Behring
Co., Marburg, FRG) at a final concentration of 15 igper 0.1 ml
for 30 minutes at 4°C. After exposure of residual erythrocytes to
isotonic ammonium chloride solution and washing in PBS,
FITC-labelled goat anti-mouse IgG (Fab)2 (Dianova Co., Ham-
burg, FRG) was added to the pellets at a final dilution of 1:30 in
PBS for 30 minutes at 4°C. After washing, specific binding of
the antibodies was analyzed by flow cytometry using FACScan
equipment (Becton Dickinson Co., Heidelberg, FRG). Cells
were identified by their light scattering properties of forward
and side scatter.
Immunohistochemical detection in cytocentrifuge prepara-
tions. Diluted cell fractions were centrifuged on amino-deriva-
tized glass slides [17] at 50 g for five minutes. The adherent cell
layer was air-dried and fixed in water free acetone or ethanol for
10 minutes at —20°C. Anti-TCC was used at a final concentra-
tion of 100 g/ml in Tris-buffered saline, pH 7.4. Detection of
mouse Mab was performed according to the alkaline phos-
phatase/anti-alkaline phosphatase technique (APAAP) [18], us-
ing commercially available antibodies (Dakopatts Co.). Finally,
cells were counter-stained with hemalaun for two minutes,
covered with glycerol gelatine under a cover slip and examined
by microscopy.
TCC dependence of monocyte activation by dialysis mem-
brane contact. Monocytes were isolated from heparinized
blood of healthy volunteers collected under sterile conditions.
Buffy coat cells were subjected to Ficoll-Paque (Pharmacia Co.,
Freiburg, FRG) density gradient centrifugation. Mononuclear
cells were carefully harvested, washed thrice in RPM! 1640
(Biochrom Co., Berlin, FRG) containing 100 U/mI penicillin and
/
+10mM EDIA
698 Deppisch el at: Ter,ninal complement complex
(addition of 0.1 M EDTA stock solution, pH 7.2). The roller
pump equipped with 1.3 mm (I.D.) silicone tubes was calibrated
before each experiment. All experiments were carried out in
duplicate with serum from the same volunteer (R.D.) being
tested in parallel with cuprophan (CU) and hemophan (HE)
capillary membranes, respectively (Akzo-Bemberg Co., Wup-
pertal, FRG; membranes taken from commercial dialyzers).
Samples of perfusion fluid were analyzed using C3a-RIA and
TCC-ELISA.
Patients and dialyzers (clinical study)
FIg. 1. Scheme of the in vitro single-path perfusion equipment with
capillary minidialyzer.
100 jsg/ml streptomycin and were adjusted to 3.5 x 106 cells/mI.
One milliliter cell suspension/well was placed for adherence (60
mm, 37°C, 7% C02) in 24-well tissue culture plates (Greiner Co,
Nürtingen, FRG) yielding a monocyte layer (0.9 to 1.0 X 106
cells/cm2) with a viability (trypan blue exclusion) of >98% and
a purity of about 90%. Monocytes were stimulated in 600 d
C8-deficient serum (20%) supplemented with a final concentra-
tions of 0.20 or 2.0 pg/ml purified C8 by sterilized cuprophan
flat membrane devices (1 cm2). Controls included medium,
purified C8 in medium (0.2 or 2.0 sg/ml), C8 deficient serum and
LPS (10 jsg/ml from S. minnesota).
After incubation for 60 minutes at 37°C (7% C02) cuprophan
membranes and supernatants were removed and 1 ml serum
free medium was added. After a second incubation for 24 hours
(37°C, 7% C02) supernatants were harvested, supplemented
with 4 mrn EDTA and 2 /LM indomethacin, centrifuged and
stored at —80°C.
PGE2 and TNFa concentrations were measured according to
the instructions of the manufacturer by RIA (NEN Dupont Co.,
Bad Homburg, FRG) and ELISA (T-Cell Sciences Co., Cam-
bridge, Massachusetts, USA), respectively.
In vitro perfusion system
The single path perfusion model is schematically depicted in
Figure 1. ETO-sterilized capillary minidialyzers (internal sur-
face approximately 300 cm2) were assembled similar to normal
sized dialyzers and rinsed before use with sterile isotonic saline
at 37°C via the "blood" and "dialysate" compartments, respec-
tively. At stable flow rate (1 mI/mm), temperature (37° 1°C)
and transmembrane pressure (below 20 mm Hg), a three-way
stopcock in the "blood" line was switched changing fluid in the
"blood" compartment from saline to prewarmed human serum.
Protein concentration during perfusion was registered by an
in-line UV-monitor. Samples were taken from the inlet and
outlet of the "blood" lines on the minidialyzer, immediately
cooled and adjusted to a final concentration of 10 mrt EDTA
After informed consent was obtained, five patients who had
been stable on maintenance hemodialysis were sequentially
studied with different dialyzers as outlined in Table 1. Relevant
clinical information is given in Table 2. Patients did not show
clinical signs of acute inflammation or hypersensitivity; they
had no history of transplantation, immunosuppression or ste-
roid medication for other reasons. The study was designed to
compare: (i) three different membrane materials (cuprophan,
hemophan and polysulfone); and (ii) two sterilization proce-
dures (ethylenoxide gas vs. steam sterilization). All dialyzers
had the same geometry and wet surface area (1.2 m2); according
to the specifications of the manufacturers, ultrafiltration coeffi-
cients, priming volumes and clearances were almost identical.
The patients were dialyzed 3 x 5 hr/week using AK-b (Gambro
AB, Lund, Sweden) at a monitored blood flow rate of 280
mI/mm (pump unit calibrated for each experiment) and at a
dialysate flow rate of 500 ml/min. Heparin (5000 U/mi sodium
salt; Braun Co., Melsungen, FRG) was used. The schedule of
heparin application was 5000 U in 1000 ml priming fluid and
1000 to 2500 U/hr during dialysis. Heparin requirements were
identical for all dialyzers with the exception of HE-ETO which
required higher doses to keep the dialyzer clear.
ETO-sterilized polyvinylchioride (PVC) blood lines from
Gambro Co. (Hechingen, FRG) were deaerated for three
months (ETO in rinsing fluid below detection limit).
Arterial (dialyzer inlet) and venous (dialyzer outlet) blood
samples were carefully drawn using 1 ml syringes (24G*
1-needle) prefilled with 0.1 ml 0.1 M EDTA solution adjusted to
pH 7.2. Bubble formation and forced aspiration were meticu-
lously avoided. Samples were immediately stored on ice.
Plasma was harvested within 30 minutes after centrifugation for
15 minutes at 4°C, 1000g. Aliquots were shock frozen, stored at
—80°C and thawed only once. Samples were collected from
patients before connecting to the extracorporeal circuit and 8,
15, 30, 60, 120 and 240 minutes after first contact of blood with
the dialyzer membrane. In order to evaluate the contribution of
tubing to foreign surface-induced complement activation, we
collected blood samples in one patient over a period of 20
minutes while the patient was connected to the short-circuited
blood line with the dialyzer in bypass position prior to hemo-
dialysis. Disappearance of TCC after discontinuation of foreign
surface contact was monitored in four additional patients after
dialysis with cuprophan (Gambro GF l8OH); blood samples
were taken during dialysis and over a period of four hours after
disconnection of the extracorporeal system.
In order to quantitate TCC irreversibly bound (in a thermo-
dynamic sense) to dialyzer membranes, dialyzers were exam-
ined ex vivo. After exhaustive rinsing (PBS-EDTA) membrane
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Table 1. Design of the clinical study
Membrane Cuprophank Cuprophan' Hemophan HemophanR Polysulfone
Sterilization ETO Steam Steam ETO ETO
Schedule (week) 1 2 3 4 5 6 7 8 9 10
Samplinga I I I I I I I I I I I I I I I I I I I
--
I I I
--
Dialyzer Gambro Gambro Gambro Gambro Fresenius
(company/type) GF 120 H GFS 120 GFPLUS 120 GFSPLUS 120 F 6
Wet surface area (m2) 1.20 1.20 1.20 1.20 1.25
Blood samples for study were taken during second dialysis treatment of each week (indicated by arrow)
Table 2. Clinical data of patients participating in the study
Duration of Predialysis
Age hemodialysis ETOaba 5Cr
Patient yr Sex Renal disease months PR U/mI mg/dl
Hct
% Dialysat&'
65 F Analget. nephrop. 27 <0.35 9.8 30.6 BEA
2 70 F Glomerulonephritis 108 <0.35 10.4 30.9 BEA
3 55 F Diabet. nephrop. 56 <0.35 12.0 30.2 HDB
4 51 F Reflux nephrop. 144 0.45 11.3 25.5 ERH
5 39 M Urin. tract obstr. 122 0.74 12.2 38.5 EFS
a IgE-antibodies against ETO given as Phadebas Rast Units (PRU/mI; Pharmacia Co, Freiburg, FRG)b Dialysate fluids: EFS: 130 mri Na, 0.5 mri Mg; HDB: 135 mri Nat, 1.0 mi Mg; BEA: 140 mi Nat, 1.0mM Mg; ERH: 150 m Na,
1.0mM Mg; all containing 1.75 mcvi 35 mi acetate (Fresenius Co, Bad Homburg, FRG).
bound proteins were eluted as described by Notohamiprodjo et
al [19] and TCC was detected by ELISA.
Control groups
EDTA plasma was collected for analysis of TCC from normal
blood donors (N = 55), patients with preterminal uremia from
non-immunological renal diseases (N =29) and dialysis patients
with severe symptoms of ETO-hypersensitivity (N = 11; blood
sampling predialysis).
Data analysis
TCC plasma concentrations were plotted and analyzed using
RS/1 software package (RS/l release 3.0; BBN Software Prod-
ucts Corporation, Cambridge, Massachusetts, USA).
Analysis of kinetics. For analysis of the kinetics of terminal
complement activation we subjected TCC values to pharmaco-
kinetic modelling based on the Bateman function [20].
D k1C(t) = — x x (e — k,1xt — e — kxt)VD kikei
where: D (pg) amount of TCC released into the fluid
phase,
VD (ml) distribution space for TCC,
k1 (min) . . . invasion constant,
kei (min 1) . elimination constant.
The model describes simultaneous invasion (net release from
dialyzer) and elimination of TCC over treatment time assuming
first order kinetics. The unknown parameters D/VD, k1 and kei
in the Bateman function were calculated by least-squares
method using the curve fitting routine of RS/1. Reasonable
goodness-of-fit was found both by inspection of the scatter of
data around the fitted curve and by calculation of the standard
error of the calculated parameters.
As an approximation we assumed that TCC in the fluid phase
released from the dialyzer partitions mainly into the plasma
space. We estimated plasma volumes by calculating for each
patient plasma volume as a function of body weight, height and
hematocrit according to Boer [21]. It is obvious that errors in
the value of VD will affect the calculated values of D, but not the
parameters of main interest in kinetic analysis, that is, k, and
kei.
From post-dialysis TCC concentrations we calculated the
elimination constant (after discontinuation of blood/foreign
surface contact) from:
C(t) = C0 x e — kpostxt
where: C0 (tg/ml) TCC at the end of the treat-
ment
(min I) elimination constant after dis-
continuation of foreign sur-
face/blood contact.
Statistical evaluation. Data are given as mean standard
deviation (SD) from duplicate measurements in five patients.
Statistical comparisons were performed applying the decision
tree of the "statistics' '-routine in RS/1. The program works
with the following hierarchy: 1.) test for normality of the
underlying distribution; 2.) parametric t-test; 3.) non-parametric
paired sample test according to Wilcoxon, or 4.) analysis of
variance (ANOVA).
Results
Purification of terminal complement complex
In order to calibrate the micro-ELISA TCC was isolated from
zymosan-activated human serum by a five step procedure.
Apparent molecular weight of TCC on gel filtration was approx-
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imately 1000 kD. Net recovery was about 1% of TCC in starting
material. High purity of TCC was documented by the sensitive
silver stained SDS-PAGE which documented bands with appar-
ent molecular weights corresponding to C5b, C6, C7, C8
alpha-gamma, C8-beta, C9 and C9-dimer. These bands result
from dissociation of TCC by SDS. Their identity with the
respective C components was confirmed by immunoblotting
(immunodetection of protein S was not unambigious). Presence
of high molecular weight contaminants were excluded by the
use of 2 to 10% gradient SDS-PAGE.
Micro-EL ISA for terminal complement
complex—Performance characteristics
Detection threshold of the TCC in normal human plasma was
approximately 40 ng/ml (Fig. 2). Assuming a molecular weight
of 1.040 kD [14, 22] for the SC5b-9 complex, this corresponds to
a molecular detection limit of 4.0 X 10 M, that is, well below
normal concentrations in EDTA plasma. Using yeast-activated
human serum, the signal was linear over a range of 40 to 2000
nglml (Fig. 2). The regression fit of the calibration curve was
better than 0.995. Intraassay variation coefficient was 2 to 7%,
interassay variation for the same specimens measured at dif-
ferent days was 10%. Variability for different venipunctures in
the same individual and on the same day was less than 5%.
Addition of varying amounts of purified TCC standards to
EDTA-plasma resulted in a parallel shift corresponding to a
basal TCC concentration in EDTA-plasma of 500 ng/ml. This
indicates 100% recovery within the limits of intraassay varia-
tion. The signal-to-noise ratio, that is, completely activated
serum/EDTA plasma, was 1000: 1. TCC concentration in 55
healthy blood donors was 611 165 nglml, In 29 patients with
preterminal renal failure from non-immunological renal diseases
TCC was 559 248 ng!ml.
Generation of terminal complement complex in
vitro—Comparison of cuprophan and hemophan minidialyzers
Figure 3 shows the TCC concentration difference (outlet
minus inlet) as a function of time for CU and HE minidialyzers,
respectively. Results for PS (not shown in the figure) were
similar to HE. The results show strikingly more net TCC
generation with CU after single-path serum perfusion at 37°C.
Consistency of results was confirmed in a replicate experiment.
Concomitant measurement of C3a levels (RIA) yielded high
baseline values (approximately 4000 nglml) and minor relative
increase over time with CU (6000 to 8000 ng/ml at 20 mm) and
no further activation with HE (4000 to 6004) ng/ml at 20 mm).
Concentrations of terminal complement complex in patients
dialyzed sequentially with cuprophan, hemophan and
polysulfone dialyzers, respectively
Figure 4A (cuprophan) shows a rapid rise of TCC concentra-
tion in dialyzer outlet reaching a maximum at approximately 30
minutes and declining monotonously thereafter. Maximal con-
centrations were 40-fold above baseline concentration. For
each treatment modality, replicate studies were done in each
individual patient; results were highly reproducible within pa-
tients. In contrast, interindividual variations, indicated by Sn in
Figure 4, were considerable. At discontinuation of dialysis,
TCC concentrations were still above baseline and declined in an
exponential fashion thereafter with a mean half-life of 48
minutes (range 42 to 58 mm) corresponding to a kei of 0.0144
min.
A significant (P < 0.0001), though less pronounced, rise in
TCC concentrations was noted when patients were dialyzed
with HE membranes (Fig. 4B. note difference in scale!). Con-
centration maximum occurred at 43 minutes, this is later than
with CU. Maximal concentration was fourfold above baseline
concentration.
Minor, but significant (P < 0.0001) increments in TCC
concentrations were also noted (Fig. 4C) when the patients
were dialyzed using PS membranes (ETO-stenlized). At 60
minutes, the difference between HE (ETO-sterilized) versus PS
was significant (P < 0.05). The average increment of venous
(outlet) TCC concentration above baseline was 40-fold for CU,
fourfold for HE and threefold for PS. Both for CU and for HE
dialyzers, a significant difference (CU: P < 0.10; HE: P <0.05;
0
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Fig. 3. In vitro formation of TCC in serUm during perfusion of cu-
prophan and hemophan minidialyzers. TCC concentrations of 2 inde-
pendent experiments are given as C01 — C,,, (ng/ml) at QB = I mi/mm.
TCC in serum reservoir changed linearly from approximately 600 nglml
at 0 mm to 1000 ng/ml at 20 mm. Constancy of protein concentration is
documented by UV-absorbance at 280 nm. Symbols are: (A, •)
cuprophan; (, J) hemophan.
Fig. 2. Calibration curve of TCC-ELISA. Each data point represents
the mean of O.D. in four wells.
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Fig. 4. Concentration-time profiles of TCC upon contact ofblood with
different dialyzer membranes. A. ETO- versus steam-sterilized cu-
prophan dialyzers. B. ETO- versus steam-sterilized hemophan dialyz-
ers. C. ETO-sterilized polysulfone dialyzers. Concentrations were
measured in arterial inlet and venous outlet. For 5 patients all individual
data from 2 independent studies are given as mean + SD. Note
differences in scale for CU vs. HE and PS. Symbols are: (•) ETO inlet;
() ETO outlet; (A) steam inlet; () steam outlet.
ANOVA for TCC data at t 60 mm in arterial inlet) was noted
between ETO sterilized and steam sterilized devices. This
occurred to a similar extent in patients with (N = 2) and without(N = 3) reagenic ETO antibodies by RAST (radioallergic
sorbent assay; courtesy Dr. Spindler, Research Laboratory,
Akzo Co., Obernburg, FRG). Baseline TCC concentration in
the two patients with borderline ETO antibodies, and in 11
patients with highly elevated ETO-ab (by RAST; patients not
included in further study) were not higher (617 124 nglml)
than in other dialysis patients.
For further examination, data were subjected to kinetic
analysis under the (simplifying) assumptions detailed in mate-
rial and methods (Table 3). Total net release from the dialyzer
calculated from kinetics (Bateman function), ignoring potential
intradialyzer turnover, was 75.5 mgover the dialysis session for
CU-ETO. The significant TCC concentration differences be-
tween membranes were paralleled by significant differences of
total net release and invasion constants, respectively. Signifi-
cant differences were found for invasion constant between CU
(ETO and steam sterilized) versus HE (steam sterilized; P =
0.0014) and for HE (ETO sterilized, but not steam sterilized)
versus PS-ETO (P = 0.031). A significant difference (P =
0.0014) was also found for HE ETO sterilized versus HE steam
sterilized, but not for CU-ETO versus CU-steam.
Total net generation, calculated as integrated concentration
difference (out-in) x plasma flow over treatment period was
consistently higher by a factor of 3 than total net release; this is
best explained by assuming that a multiplicative factor was
ignored in the calculation of the total release (D).
Significant differences were also found for elimination rate
constants between CU and the other dialyzers, but they were
not detectable between sterilization procedure.
A control experiment showed no significant increment in
TCC concentration when blood was circulated through PVC
tubing for 20 minutes. Subsequent to PVC exposure, inert with
respect to TCC generation, the usual TCC response to PS was
observed in the following hemodialysis session.
After elution with 1% Triton X-100/l0 m'vi EDTA, a mean of
500 p.g immunoreactive TCC was recovered from 1 m2 mem-
brane area of cuprophan and 280 tg from polysulfone.
Comparison of comple,nent anaphylatoxins and terminal
complement complex during hemodialysis with cuprophan,
hemophan and polysulfone dialyzer
No measurable baseline values for C5a could be measured in
two of five patients, but measurable baseline values were found
for C3a in all patients (Table 4). For the calculation it was
assumed that baseline C5a concentration corresponded to de-
tection threshold. Ratio of maximal versus basal concentrations
with CU membranes, both in inlet and outlet, were seen to be
lower for the anaphylatoxins (C3a and C5a) than for TCC.
Conversely, with HE and PS membranes (ETO-sterilized), the
ratio (outlet) was higher for C3a versus TCC. The concentration
time profile for TCC showed a delayed time to the peak.
Demonstration of terminal complement complex on blood
cells
Measurements in the fluid phase assess only biologically inert
SC5b-9, that is, TCC bound by the scavenger molecule S-
protein. Since biological effects on cells can only be exerted by
membrane bound TCC, we evaluated whether blood cells of
dialysis patients acquire TCC during a dialysis session. Pa-
tients' polymorphonuclear cells (PMN) were examined prior to
and at various times during dialysis (using CU dialyzer ETO-
sterilized). Flow cytofluorometry technique was applied. After
reaction with Mab against TCC neoantigen followed by FITC-
conjugated secondary antibody, control PMN (as defined by
forward and side scatter) gave a reproducible low intensity,
unimodally distributed fluorescence signal spanning two dec-
ades. Compared to baseline, PMN isolated 8, 15 and 30 minutes
after start of dialysis, gave fluorescence signals which were
higher than the highest signal of patients' PMN at baseline or of
control patients. The percentage of high fluorescence (>102
times baseline) PMN increased with time from 0.7% (8 mm) to
1.4% (30 mm). PMN numbers, as counted by the cytometer,
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Table 3. Kinetic parameters of terminal complement complex—comparison of membranes and sterilization procedures
Cbasai
ng/m!
c a
io ng/m!
tmaxb
mm
Max net
ratec of
generation
xg/min
Total netd
generation
Total releasee
from dialyzer InvasionconstantlO min'
Elimination
constant
l0- min'mg
CU-ETO 584 208 22.9 5.5
(11.3 3.8)
33.9 8.2
(70.6 7.5)
3136 928 233 81.2 75.5 20.7
(59.4 41.4)
88 27
(26 8)
63 13
(71 31)
CU steam 625 259 20.4 5.4
(10.1 3.2)
34.4 11.9
(76.2 14.1)
2920 966 225 59.9 74.3 23.0
(55.3 28.2)
87 40
(25 11)
69 24
(77 23)
HE-ETO 634 246 2.45 1.1
(1.35 .53)
43.0 14.5
(45.2 15.8)
257 150 30.1 15.2 7.3 4.1
(4.5 2.1)
90 22
(88 28)
30 10
(18 11)
HE steam 578 95 2.17 .80
(1.00 .23)
28.5 9.8
(51.9 19.8)
248 143 28.2 11.9 6.65 3.4
(2.95 .89)
163 62
(138 47)
36 16
(14 9)
PS-ETO 533 112 1.65 .42
(0.89 .17)
30.8 14.7
(41.3 8.2)
175 74 15.9 5.3 5.01 1.7
(2.74 .71)
168 88
(127 35)
34 14
(13 5)
Individual data of 5 patients in 2 independent studies (Table I) are given as mean SD. Kinetic parameters were calculated using venous outlet
concentrations (in brackets: arterial inlet concentrations).
a maximal TCC concentrationsb time of maximal TCC concentration (minutes after first blood/membrane contact); taken from fitted curves
maximum rate of net generation calculated as (C0, — C1,,) X Q x (1 — Hct/lOO) at approx. 15 mm
a total net generation calculated as (,.j'240(C0,,,(t) — C,,(t)) x dt) >< Q X (1 — Hct/100)
e total release from dialyzer as calculated by kinetic analysis (Bateman function) assuming plasma volume as space of distribution
Table 4. Comparison of C3a, C5a and TCC during dialysis with cuprophan (CU), hemophan (HE) and polysulfone (PS) membranes
Membranea
C3a C5&' TCC
CU HE PS CU HE PS CU HE PS
Basal value
ng/ml
CmaxinietRatio C
CmatletCRatio Cbasal
tmax mind
Molar detection
limit (M) of assays
395
8.4
35.3
8—15
3.6 x l0—
492
3.6
10,3
8—30
508
2.4
5.7
2.1
6.9
8—15
7.3
2.0
2.7
15—30
1.1 x 10"
10.5
1.4
1.7
15—60
485
25.8
50.0
33.9
596
2.4
3.9
43.0
4.0 x
502
1.8
3.3
30.8
All dialyzers were ETO-sterilized; data as mean SD of N = 4 patients for C3a and TCC and 3 patients for C5a
b C5a data are approximations because of RIA baseline values below threshold in many patients
C Means of ratios calculated from concentrations in each individual patient
d Time at maximal concentration (in outlet); for TCC tmax was extracted from fitted curves
decreased by 87% from 0 to 30 minutes. PMN sampled concur-
rently at corresponding times in a non-dialyzed healthy control
showed no PMN with high fluorescence intensity. These find-
ings were confirmed in three different patients with no overlap
of values before and after membrane contact.
To confirm acquisition of cell bound TCC by an independent
method, we examined PMN samples at corresponding times of
dialysis in cytofuged preparations using APAAP techniques
(Fig. 5). At baseline or in controls, occasional PMN were noted
with clumpy material showing staining for TCC of low intensity.
By 30 minutes after beginning of dialysis (CU-ETO), many
PMN were demonstrable which showed intense staining (Fig.
5). Control specimens with non-immune ascites or omission of
specific Mab were consistently negative.
TCC dependence of monocyte activation by dialysis
membrane contact
Monocytes of healthy donors, adherent to polystyrene and
contacted with cuprophan for 60 minutes, showed low baseline
generation of PGE2 and TNFQ, respectively, in medium or C8
deficient serum. Addition of various amounts of C8 resulted in
parallel increase of TCC, PGE2 and TNFa (Table 5).
Discussion
In the present study, a micro-ELISA for terminal comple-
ment complex (TCC) with low detection limit and good perfor-
mance characteristics was developed. The results show that
TCC concentrations in the fluid phase consistently rise upon
blood/membrane interaction both in vitro and in patients on
maintenance hemodialysis. The increment in TCC was higher in
membranes with known bioincompatibility and was demonstra-
ble even for membranes which have not been thought to
activate complement, such as, polysulfone. C-activation is
generally considered as a good index of bioincompatibility [23].
To date, most measurements were carried out using radioim-
munoassays for C3a and CSa. We feel that measurements of
TCC are a useful extention of these studies and yield comple-
mentary information. Potential disadvantages of the cationic
anaphylatoxins as parameters of bioincompatibility include high
nonspecific adsorption on membranes, for example, dialyzer
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Fig. 5. Immunohistochemical staining (APAAP) of terminal comple-
ment complex (TCC) deposited on cells, Preparations of PMN from
blood drawn 8 mm (A) and 30 mm (B) after first contact of blood with
CU membranes. Levamisol/Fast Red (Sigma Co) was used as insoluble
substrate.
Table 5. C8 supplementation of C8 deficient serum increases
generation of PGE2 and TNFa by adherent monocytes (0.9 —
1.0 x 106 cells/cm2, 1 cm2 cuprophan, mean SD of
N = 4 experiments)
Medium
control
C8 def serum
C8 def
serum
+0.2 pg
C8/ml
+2.0 pg
C8/ml
TCC ng/ml
POE2 pg/ml
TNF pg/ml
<400a
72 12
103 30
<400°
66 11
185 46
455 70
148 25
178 40
4145 160
2450 416
398 95
a Below detection limit
membranes or cell membranes. High baseline values of C3a and
C5a, as measured by RIA in this study and in previous
investigations [24, 25], presumably overestimate in vivo con-
centrations. One would predict occupation of all receptors if
such concentrations were really present in vivo. We conclude
that C3a measurements are more reliable, but we had consid-
erable diffIculties with analysis of CSa: first, concentrations in
plasma of the C5a precursor CS are considerably lower (by
1/300) than of the C3a precursor C3; second, given the high
biological activity of C5a, baseline values of 10 ng/ml appear
implausibly high, and our failure to measure baseline C5a in
patients may therefore be real; third, fluid phase concentrations
of CSa are difficult to interpret in view of avid specific and
nonspecific binding of CSa.
The present micro-ELISA for TCC using monoclonal anti-
body compares favorably with assays described in the past
[26—28]: it has low detection limit, high signal-to-noise ratio and
low intraassay or interassay variation. Previous investigators
showed that TCC may be used as a monitor of in vivo
C-activation in inflammatory diseases [29—31], or in cardiopul-
monary bypass surgery [321. Our assay does not discriminate
between SC5b-9 and MC5b-9. Monitoring TCC concentrations
conceivably offers several advantages. First, a more distal
component of the C-system may be more highly amplified
within the complement cascade, and this is suggested by some
of our findings. Second, while the cationic C-anaphylatoxins
bind to dialyzer membranes, TCC does not readily bind to a
major extent as shown by our analysis. In the case of hydro-
phobic synthetic membranes, we would predict that little free
energy will be available for further interaction with partly
hydrophobic surfaces once hydrophobic interaction with S-
protein has occurred. Finally, significant loss by filtration, as
for C3a and C5a [33, 34], cannot occur because of high
molecular weight of TCC, a point of note given by the recent
interest in novel high flux membranes. In the future it may be
advantageous to monitor the C system simultaneously at dif-
ferent levels.
In our study, TCC concentrations were not a linear function
of C3a and C5a concentrations, respectively. Whether this
reflects only differences in adsorption to dialyzer membranes
and blood cells, or whether this points to more fundamental
differences in kinetics of generation remains to be demon-
strated. A consistent feature of our kinetic analysis was the
delay of tmax for TCC relative to that for C3a and C5a. The
causes of this are under investigation.
Monitoring of TCC was used to compare membranes in a
newly developed in vitro minidialyzer setup. This system holds
promise for preclinical screening of new biomaterials. The
present design differs from past models [35, 36] by its capillary
geometry which allows operation at very low serum volumes
and controlled variable low flow rates. C3a concentrations after
prewarming to 37°C were relatively high at baseline and showed
little further increase after membrane contact. In contrast, TCC
concentrations were low at baseline and increased fivefold over
20 minutes. The ranking of membranes, that is, CU >> HE>
PS corresponded to the in vivo results.
The protocol for in vivo analysis was carefully validated.
Patients were always examined during midweek dialysis at
similar hydration status. Great care was taken to standardize
conditions of blood withdrawal and work up; this was reflected
by low coefficient of variation of repeat analysis. Factors like
standardization and continuous monitoring of blood flow, ul-
trafiltration rate, heparin dosage, accuracy of timing of blood
withdrawal, were presumably responsible for very low differ-
ences between replicate measurements when the same patient
was re-exposed to the same procedure. No TCC was generated
when blood was percolated through PVC tubing, demonstrating
that TCC was generated by contact of blood with the dialyzer
membrane.
The observation of rapidly declining C3a concentrations 30
minutes after blood/membrane contact [37] led to the proposal
that C-activation within the dialyzer largely ceased after mask-
ing of C3 activation sites. In the present study we were struck
by the observation of positive outflow/inflow concentration
differences despite declining C3a, C5a and TCC concentrations
after peak concentrations were reached approximately 15 or 30
minutes subsequent to start of dialysis. This prompted us to
carry out kinetic analysis using an established pharmacokinetic
model. Concentration-time profiles were well described assum-
ing an open one-compartment model and first order kinetics. By
0 
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necessity, the dialyzer remained a black box; adsorption to the
membrane, filtration or degradation of TCC within the dialyzer
escaped detection. As a first approximation, total net release of
TCC from the dialyzer was calculated by Bateman function
assuming a space of distribution equal to plasma volume. When
these values were compared with total net generation (calculat-
ed from plasma flow x a-v difference), the latter was consis-
tently higher by a factor of 3. This observation implied that a
multiplicative factor had been neglected in the assumption of
distribution space. The true distribution space was presumably
higher as a result of adsorption to cell membranes or endocy-
tosis.
The rate of generation of TCC was not linear with time but
showed a distinct maximum at 15 minutes for CU, HE and PS
membranes, respectively. It declined exponentially thereafter.
At least in the fluid phase, less than 5% of precursor proteins of
the SC5b-9 complex were recovered in the TCC; consequently,
exhaustion of precursor proteins presumably did not occur
during hemodialysis.
A similar ranking CU >>> HE> PS (all ETO sterilized) was
seen for Cmax, maximal net rate of generation or for total
generation. In contrast, invasion constants were similar for
CU/HE-ETO, but greater for PS/HE-steam. Surprisingly, elim-
ination constants differed significantly between CU and HE or
PS, respectively. This would imply that some membrane char-
acteristics determine elimination for TCC from the fluid phase.
Since binding of TCC from recirculating blood to the dialyzer
membrane was low, the most likely explanation is that some
proximate effects of membrane contact, such as activation of
PMN and/or monocytes followed by endocytosis, are respon-
sible for faster elimination of TCC with use of more bioincom-
patible membranes. After discontinuation of hemodialysis,
TCC elimination coefficient changed to a value of 144 x l0-
min. This figure is in reasonable agreement with previous
estimates of Mollnes [38].
Ethylenoxide (ETO) is still widely used as a gas sterilizing
agent. It has been shown to cause anaphylactic complications
on dialysis which are mediated via reagenic antibodies [39]. The
present observation of significant differences in TCC generation
between steam sterilized and ETO sterilized dialyzers docu-
ments another adverse effect of ETO. The difference was small,
but consistent and significant. The difference was more marked
for arterial (inlet) concentrations. Detection of the small (ap-
prox. 10%) difference was presumably possible because of the
design of the study (intraindividual comparisons) and analytical
accuracy. The mechanisms by which ETO causes higher TCC
concentrations have not been defined. Reagenic reactions, that
is, interaction with IgE antibodies, with basophils and mast
cells, are not known to activate complement. We cannot
exclude that proteases released from blood cells, such as
granulocytes, influence TCC generation. The possibility of
direct generation of TCC by an ETO reaction product is
suggested by preliminary observations: contact of serum with
ETO-sterilized polyurethane slices, but not ETO or polyure-
thane itself, induced in vitro formation of TCC (unpublished
data).
TCC in the fluid phase is thought to represent a biologically
inert scavenger product, while in contrast cell damage of
erythrocytes [40], and cell activation of nucleated cells occur
through hydrophobic complexes which insert into the cell
membrane [41]. Cell activation has been shown for human
neutrophils [42], platelets [43, 44], monocytes [45] and other
somatic cells [46]. Insertion of TCC into erythrocytes on
patients on cardiopulmonary bypass has been demonstrated
[32]. Non-lethal complement membrane attack on PMN has
been shown to lower response to chemotactic or phagocytic
stimuli [42], a finding similar to the functional defect in PMN
during dialysis observed by Lewis, Van Epps and Chenoweth
[47].
In an effort to further clarify whether cell (membrane) bound
TCC can be demonstrated in dialysis patients, we used two
different approaches: flow cytofluorometry and detection of
TCC on PMN immunostaining (APAAP technique) of cytofuge
preparations. With both techniques, TCC could be demon-
strated on a small proportion of PMN. These findings may
underestimate the number of cells acquiring TCC since such
cells may be preferentially sequestered in the pulmonary mi-
crovasculature.
In the past, the effect of TCC has mainly been monitored by
lysis of cells, such as erythrocytes. The effect of TCC as an
agent activating nucleated cells has been recognized more
recently. In monocytes or mesangial cells, TCC causes gener-
ation of effector proteins like IL-i, TNF, of lipoxygenase
products, oxygen burst products and arachidonic acid products
[45, 46, 48]. It is of interest that some of these effectors have
also been implicated in the pathogenesis of bioincompatibility
reactions [49, 50]. To further investigate whether release of
these mediators is related to TCC generation by dialysis mem-
brane contact we examined the effect of exposure of adherent
monocytes to cuprophan in C8 deficient serum and after addi-
tion of C8. Low generation of PGE2 and TNF was noted in C8
deficient serum, compatible with the observation of Arend et al
[51] that C5a fails to increase IL-I release. Making the plausible
assumption that TCC generated in response to addition of C8 is
interacting with cell membranes, the observation indicates cell
activation related to TCC.
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Appendix. Abbreviations
Mab monoclonal antibody
C
TCC
ELISA
RIA
CU
HE
PS
ETO
complement
terminal complement complex
enzyme linked immunosorbent assay
radioimmunoassay
cuprophan (cuprammonium) membrane
hemophan membrane
polysulfone membrane
ethylenoxide
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SCSb-9 S-protein bound fluid phase terminal complement
complex
membrane bound terminal complement complex
alkaline phosphatase/anti-alkaline phosphatase
phosphate buffered saline
Tris buffered saline
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